• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis.

作者信息

Seufert Jochen, Lanzinger Stefanie, Danne Thomas, Bramlage Peter, Schmid Sebastian M, Kopp Florian, Kress Stephan, Fasching Peter, Schäfer Claus, Holl Reinhard W

机构信息

Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Institute for Epidemiology and Medical Biometry, ZIBMT, University of Ulm, Ulm, Germany.

出版信息

Diabetes Obes Metab. 2022 Apr;24(4):742-746. doi: 10.1111/dom.14620. Epub 2021 Dec 23.

DOI:10.1111/dom.14620
PMID:34897941
Abstract
摘要

相似文献

1
Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis.来自德国/奥地利糖尿病患者数据注册中心的1型糖尿病患者使用钠-葡萄糖协同转运蛋白2抑制剂进行12个月辅助治疗的真实世界数据：糖化血红蛋白改善且无糖尿病酮症酸中毒。
Diabetes Obes Metab. 2022 Apr;24(4):742-746. doi: 10.1111/dom.14620. Epub 2021 Dec 23.
2
Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries.对比 2622 名美国 T1DExchange 和德国/奥地利 DPV 注册处年龄小于 6 岁的 1 型糖尿病患儿的临床护理和结局。
Diabetologia. 2014 Aug;57(8):1578-85. doi: 10.1007/s00125-014-3272-2. Epub 2014 Jun 4.
3
Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.钠-葡萄糖协同转运蛋白2抑制剂作为1型糖尿病胰岛素治疗的附加疗法：随机对照试验的系统评价和荟萃分析
Diabetes Obes Metab. 2018 Jul;20(7):1755-1761. doi: 10.1111/dom.13260. Epub 2018 Mar 25.
4
Review: In adults with type 1 diabetes, SGLT-2 inhibitors reduce HbA1c but increase diabetic ketoacidosis.综述：在1型糖尿病成人患者中，钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂可降低糖化血红蛋白（HbA1c）水平，但会增加糖尿病酮症酸中毒的发生风险。
Ann Intern Med. 2018 Jul 17;169(2):JC3. doi: 10.7326/ACPJC-2018-169-2-003.
5
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review.钠-葡萄糖协同转运蛋白 2 抑制剂在 1 型糖尿病中的应用：一项范围综述。
Horm Res Paediatr. 2023;96(6):620-630. doi: 10.1159/000527653. Epub 2022 Oct 24.
6
Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.1型糖尿病患者中钠-葡萄糖协同转运蛋白2抑制剂的使用与糖尿病酮症酸中毒发生率
Diabetes Care. 2020 Jan;43(1):90-97. doi: 10.2337/dc19-1481. Epub 2019 Oct 10.
7
Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.钠-葡萄糖共转运蛋白 2 抑制剂与 2 型糖尿病患者糖尿病酮症酸中毒风险：一项随机对照试验的系统评价和荟萃分析。
Diabetes Obes Metab. 2020 Sep;22(9):1619-1627. doi: 10.1111/dom.14075. Epub 2020 May 21.
8
SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.SGLT2 抑制剂在伴有糖尿病肾病的 1 型糖尿病中的应用：潜在的心肾获益可能超过可预防的糖尿病酮症酸中毒风险。
Curr Diab Rep. 2022 Jul;22(7):317-332. doi: 10.1007/s11892-022-01471-2. Epub 2022 May 28.
9
Impact of Maternal Country of Birth on Type-1-Diabetes Therapy and Outcome in 27,643 Children and Adolescents from the DPV Registry.母亲出生国家对德国糖尿病患者数据库中27643名儿童和青少年1型糖尿病治疗及预后的影响
PLoS One. 2015 Aug 21;10(8):e0135178. doi: 10.1371/journal.pone.0135178. eCollection 2015.
10
The Transatlantic HbA gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registry.跨大西洋糖化血红蛋白差距：美国 T1D 交换注册中心和德国/奥地利 DPV 注册中心纳入人群的血糖控制在整个生命周期中的差异。
Diabet Med. 2020 May;37(5):848-855. doi: 10.1111/dme.14148. Epub 2019 Oct 14.

引用本文的文献

1
Clinical characteristics, treatment, and treatment switch after molecular-genetic classification in individuals with maturity-onset diabetes of the young: Insights from the multicenter real-world DPV registry.在青年发病的成年型糖尿病患者中进行分子遗传学分类后的临床特征、治疗和治疗转换：来自多中心真实世界 DPV 登记处的见解。
J Diabetes. 2024 Nov;16(11):e70028. doi: 10.1111/1753-0407.70028.
2
Sodium-Glucose Co-transporter-2 Inhibitors in Type 1 Diabetes Mellitus: The Framework for Recommendations for Their Potential Use.1型糖尿病中钠-葡萄糖协同转运蛋白2抑制剂：关于其潜在应用的推荐框架
Diabetes Ther. 2024 Dec;15(12):2445-2453. doi: 10.1007/s13300-024-01657-9. Epub 2024 Oct 16.
3
Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives.
钠-葡萄糖协同转运蛋白2抑制剂与心脏病：当前观点
World J Cardiol. 2024 May 26;16(5):240-259. doi: 10.4330/wjc.v16.i5.240.
4
SGLT2 Inhibitors in the Management of Type 1 Diabetes (T1D): An Update on Current Evidence and Recommendations.钠-葡萄糖协同转运蛋白2抑制剂在1型糖尿病（T1D）管理中的应用：当前证据与建议的最新进展
Diabetes Metab Syndr Obes. 2023 Nov 9;16:3579-3598. doi: 10.2147/DMSO.S240903. eCollection 2023.
5
The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats.达格列净对1型糖尿病大鼠心脏重塑、心肌功能及代谢组学的影响
Diabetol Metab Syndr. 2023 Oct 31;15(1):223. doi: 10.1186/s13098-023-01196-6.
6
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.SGLT2i 和 GLP-1RA 治疗 1 型糖尿病和肾血管结局：一项真实世界研究。
Diabetologia. 2023 Oct;66(10):1869-1881. doi: 10.1007/s00125-023-05975-8. Epub 2023 Jul 28.
7
Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment.1型糖尿病患者对SGLT2抑制剂和GLP-1受体激动剂超说明书用药的感知获益与风险：一项结构化定性评估
Ther Adv Endocrinol Metab. 2023 Jun 29;14:20420188231180987. doi: 10.1177/20420188231180987. eCollection 2023.
8
A perspective on treating type 1 diabetes mellitus before insulin is needed.关于在需要胰岛素之前治疗1型糖尿病的观点。
Nat Rev Endocrinol. 2023 Jun;19(6):361-370. doi: 10.1038/s41574-023-00816-5. Epub 2023 Mar 13.
9
Sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?1型糖尿病中钠-葡萄糖协同转运蛋白2抑制剂：心血管保护的错失良机？
Med J Aust. 2022 Aug 1;217(3):126-128. doi: 10.5694/mja2.51637. Epub 2022 Jun 30.
10
Effects of the SGLT2 Inhibition on Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats, a Model of Type 1 Diabetes Mellitus.SGLT2抑制对链脲佐菌素诱导的糖尿病大鼠心脏重塑的影响，1型糖尿病模型
Antioxidants (Basel). 2022 May 17;11(5):982. doi: 10.3390/antiox11050982.